Corcept Therapeutics CORT
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Corcept Therapeutics (CORT) Business Model and Operations Summary
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Key Insights
Corcept Therapeutics (CORT) Core Market Data and Business Metrics
Latest Closing Price
$91.93Market Cap
$9.78 BillionPrice-Earnings Ratio
74.74Total Outstanding Shares
104.78 Million SharesTotal Employees
352Dividend
No dividendIPO Date
April 14, 2004SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
101 Redwood Shores Parkway, Redwood City, CA, 94065
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities | $-177.60 Million |
| Net Cash Flow From Operating Activities | $198.07 Million |
| Net Cash Flow From Financing Activities | $-28.35 Million |
| Net Cash Flow, Continuing | $-7.89 Million |
| Net Cash Flow | $-7.89 Million |
| Net Cash Flow From Investing Activities, Continuing | $-177.60 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Benefits Costs and Expenses | $513.55 Million |
| Costs And Expenses | $538.09 Million |
| Income Tax Expense/Benefit | $20.28 Million |
| Net Income/Loss Attributable To Parent | $141.21 Million |
| Basic Earnings Per Share | $1.35 |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $140.38 Million |
| Comprehensive Income/Loss Attributable To Parent | $140.38 Million |
| Other Comprehensive Income/Loss | $-826,000 |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Fixed Assets | $2.69 Million |
| Assets | $840.55 Million |
| Liabilities | $160.96 Million |
| Equity | $679.59 Million |
| Other Current Liabilities | $125.40 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||